European Primary Care Cardiovascular Society

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 2, 2022 - Prof. Richard Hobbs, MD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz

Adverse pregnancy outcomes reduced with treatment of chronic hypertension

3' education - Apr. 3, 2022 - Prof. Alan Tita, MD, PhD

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Enablement of RAASi therapy in HF using novel potassium binders

10' education - Mar. 8, 2022 - Prof. Javed Butler, MD and prof. Giuseppe Rosano, MD, PhD

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Colchicine in coronary disease: From studies to clinical practice

5' education - Mar. 1, 2022 - Aernoud Fiolet, MD, PhD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Global disparities in diagnosis and treatment of homozygous FH

5' education - Feb. 7, 2022 - Tycho Tromp, MD

A non-steroidal MRA in T2DM and CKD: Interpreting findings of studies

10' education - Feb. 1, 2022 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD - Online CME

The 2021 Polish guidelines on diagnosis and therapy of lipid disorders

5' education - Dec. 7, 2021 - Prof. Maciej Banach, MD, PhD

An algorithm-based program for cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD

Recommendation for use of icosapent ethyl in final guidance by NICE

News - July 19, 2022

NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.

Absolute risk reductions with ezetimibe and PCSK9i across different CVD risk groups

Literature - July 18, 2022 - Khan SU, et al. - BMJ. 2022

A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.

In lower-income countries, association of prolonged sitting with mortality is more pronounced

Literature - July 11, 2022 - Li S, et al. - JAMA Cardiol. 2022

Prolonged sitting is related to mortality and CVD in high-income countries. Whether this is also true for low- and middle-income countries was investigated in a study using data from the Prospective Urban Rural Epidemiology (PURE) study.

Statin intolerance newly defined by NLA

News - July 11, 2022

The National Lipid Association (NLA) has published a new scientific statement on statin intolerance, which includes a new definition and key consideration for ASCVD risk reduction in patients who are statin intolerant.

Two DOACs compared for recurrent VTE and bleeding in patients with VTE

Literature - July 6, 2022 - Dawwas GK, et al. - Ann Intern Med. 20

DOACs such as apixaban and rivaroxaban are increasingly prescribed to patients with VTE, but the results of trials directly comparing these agents are not available. What can we conclude from a retrospective cohort study?

Two DOACs compared in AF patients

Literature - July 4, 2022 - Ray WA, et al. - JAMA. 2021

A difference between the DOACs apixaban and rivaroxaban is that apixaban is taken twice daily, whereas a single daily dose is sufficient for rivaroxaban. How do the efficacy and safety of both anticoagulants compare in patients with AF?

Association of CVD risk with LDL-c is sex specific

Literature - July 4, 2022 - Cupido AJ, et al. - J Am Heart Assoc. 2022

The causal effect of LDL-c on CVD risk was stronger in male than in female participants of the UK Biobank cohort, suggesting that LDL‐c is a less important predictor of CVD risk in women than in men.

LDL-c goal is reached by nearly all patients when PCSK9i is added to optimal statin therapy

Literature - June 28, 2022 - Landmesser U, et al. - Eur J Prev Cardiol. 2022

In a subanalysis of the ODYSSEY OUTCOMES trial, 95% of patients with recent acute coronary syndrome (ACS) achieved LDL-c <1.4 mmol/L when alirocumab was added to optimal statin therapy, instead of only 17% with placebo.

Cognitive function affected by new brain infarcts in AF patients, despite anticoagulation

Literature - June 20, 2022 - Kühne M, et al. - Eur Heart J. 2022

In a large cohort of AF patients, new brain infarcts occurred frequently, despite a high anticoagulation rate. Both clinically overt and silent brain infarcts were associated with cognitive decline.

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Similar association of smoking and its cessation with HFpEF and HFrEF

Literature - June 15, 2022 - Ding N, et al. - J Am Coll Cardiol. 2022

Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.

Dual GIP and GLP-1 receptor agonist in obese individuals results in substantial weight loss

Literature - June 13, 2022 - Jastreboff AM, et al. - N Engl J Med. 2022

Tirzepatide has an agonistic effect not only on the GLP-1 receptor, but also on the glucose-dependent insulinotropic polypeptide (GIP) receptor. Whether this leads to substantial weight reduction in obese individuals without T2DM was investigated in the SURMOUNT-1 trial.